As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Arcutis Biotherapeutics Inc. The largest reported stake is BlackRock, Inc.'s, at 14.1%. 13 filings are on record since August 14, 2025 (Schedule 13G/A, October 5, 2026).
Sell to companies like Arcutis Biotherapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: BlackRock, Inc. · Sole voting: 17,576,492 · Shared voting: 0 · Sole dispositive: 17,751,435 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-05
- · Reporting person: Polar Capital Holdings Plc · Sole voting: 6,606,945 · Shared voting: 0 · Sole dispositive: 6,606,945 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-14
- · Reporting person: State Street Corporation · Sole voting: 0 · Shared voting: 5,507,182 · Sole dispositive: 0 · Shared dispositive: 5,822,840 · SCHEDULE 13G, 2026-08-07
- · Holder: State Street Corporation · Percent: 5.1% · SCHEDULE 13G
- · Holder: Prudential Financial Inc · Percent: 4.3% · SCHEDULE 13G/A
Arcutis Biotherapeutics Inc has 13 Schedule 13D or 13G filings on record since 2025-08-14. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BlackRock, Inc. | 14.1% | 17,751,435 | SCHEDULE 13G/A, 2026-10-05 | 2026-09-30 |
| Frazier Life Sciences VIII, L.P. | 7.5% | 8,785,284 | SCHEDULE 13D/A, 2025-08-20 | 2025-08-18 |
| Rubric Capital Management LP | 6.75% | 8,271,577 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
| Polar Capital Holdings Plc | 5.28% | 6,606,945 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| State Street Corporation | 4.7% | 5,822,840 | SCHEDULE 13G, 2026-08-07 | 2026-06-30 |
| Prudential Financial Inc | 4.3% | 5,302,713 | SCHEDULE 13G/A, 2026-05-08 | 2026-03-31 |
| Jennison Associates LLC | 4% | 4,980,770 | SCHEDULE 13G/A, 2026-05-06 | 2026-03-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Holding shares or following this stake? See who's behind Arcutis Biotherapeutics Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Arcutis Biotherapeutics Inc and the records around it.
Arcutis Biotherapeutics Inc elsewhere on the record
- Leadership changes Aug 2026
- Who owns it
Companies that share a holder
- Polar Capital Holdings Plc also filed stake reports on 3 other companies: Verastem, Inc. (Jul 2026), ENLIVEN THERAPEUTICS, INC. (Jun 2026), HAGERTY, INC. (Sep 2025)
- Jennison Associates LLC also filed stake reports on 14 other companies: LENDINGTREE INC (Oct 2026), PALVELLA THERAPEUTICS INC (Oct 2026), REZOLUTE INC (Oct 2026)
- PRUDENTIAL FINANCIAL INC also filed stake reports on 20 other companies: National Healthcare Properties, Inc. (Oct 2026), Neurogene Inc. (Oct 2026), PALVELLA THERAPEUTICS, INC. (Aug 2026)
Watch Arcutis Biotherapeutics Inc
Get an email when Arcutis Biotherapeutics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Arcutis Biotherapeutics Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Arcutis Biotherapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Arcutis Biotherapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 17,576,492 | 0 | 17,751,435 | 0 | SCHEDULE 13G/A, 2026-10-05 |
| Polar Capital Holdings Plc | 6,606,945 | 0 | 6,606,945 | 0 | SCHEDULE 13G, 2026-08-14 |
| Polar Capital LLP | 6,606,945 | 0 | 6,606,945 | 0 | SCHEDULE 13G, 2026-08-14 |
| State Street Corporation | 0 | 5,507,182 | 0 | 5,822,840 | SCHEDULE 13G, 2026-08-07 |
The latest filing identifies Arcutis Biotherapeutics Inc by CUSIP 03969K108 and gives its principal executive office as 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE, CA 91361 (SCHEDULE 13G/A, 2026-10-05).
Purpose of Transaction (Item 4)
Frazier Life Sciences VIII, L.P.
FLS VIII, FHM Life Sciences VIII, L.L.C, FLS X, FLSPF, FLSPOF, FLS XI and FLS XII each acquired the FLS VIII Shares (as defined below), the FHM Life Sciences VIII, L.L.C. Shares (as defined below), the FLS X Shares (as defined below), the FLSPF Shares (as defined below), the FLSPOF Shares (as defined below), the FLS XI Shares (as defined below) and the FLS XII Shares (as defined below), as the case me be, for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, FLS VIII, FHM Life Sciences VIII, L.L.C, FLS X, FLSPF, FLSPOF, FLS XI and FLS XII and other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-08-20; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Polar Capital Holdings Plc | 4.2% | SCHEDULE 13G/A |
| 2025-08-20 | Frazier Life Sciences VIII, L.P. | 7.5% | SCHEDULE 13D/A |
| 2025-10-06 | Jennison Associates LLC | 10.2% | SCHEDULE 13G/A |
| 2026-01-30 | Jennison Associates LLC | 5.5% | SCHEDULE 13G/A |
| 2026-02-13 | Rubric Capital Management LP | 6.75% | SCHEDULE 13G/A |
| 2026-02-13 | Prudential Financial Inc | 5.7% | SCHEDULE 13G/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-05-06 | Jennison Associates LLC | 4% | SCHEDULE 13G/A |
| 2026-05-08 | Prudential Financial Inc | 4.3% | SCHEDULE 13G/A |
| 2026-05-12 | State Street Corporation | 5.1% | SCHEDULE 13G |
| 2026-08-07 | State Street Corporation | 4.7% | SCHEDULE 13G |
| 2026-08-14 | Polar Capital Holdings Plc | 5.28% | SCHEDULE 13G |
| 2026-10-05 | BlackRock, Inc. | 14.1% | SCHEDULE 13G/A |
Questions about who owns Arcutis Biotherapeutics Inc
Who owns Arcutis Biotherapeutics Inc?
On this page, 4 holders' latest ownership filings report 5% or more of Arcutis Biotherapeutics Inc: BlackRock, Inc. (14.1%, Schedule 13G/A, filed 2026-10-05), Frazier Life Sciences VIII, L.P. (7.5%, Schedule 13D/A, filed 2025-08-20), Rubric Capital Management LP (6.75%, Schedule 13G/A, filed 2026-02-13) and Polar Capital Holdings Plc (5.28%, Schedule 13G, filed 2026-08-14).
Who are the largest shareholders of Arcutis Biotherapeutics Inc?
By the share each holder's latest filing reports, the largest holders of Arcutis Biotherapeutics Inc on this page are BlackRock, Inc. (14.1%), Frazier Life Sciences VIII, L.P. (7.5%) and Rubric Capital Management LP (6.75%).
When did BlackRock, Inc. buy into Arcutis Biotherapeutics Inc?
The filings give report dates, not purchase dates. The earliest filing from BlackRock, Inc. on this page is the Schedule 13G/A, filed 2026-10-05, reporting 14.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 13 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Arcutis Biotherapeutics Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 28, 2026 | Leadership change: Robert Scott appointed, Director | — | Leadership changes | Source |
| August 5, 2026 | Leadership change: L. Todd Edwards departs, and 1 more | — | Leadership changes | Source |
| July 16, 2026 | Leadership change: Christopher Peetz appointed, Director | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Arcutis Biotherapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.